Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr 1;49(4):e369-e380.
doi: 10.1097/CCM.0000000000004848.

Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial

E Vincent S Faustino  1 , Leslie J Raffini  2 , Sheila J Hanson  3 , Jill M Cholette  4 , Matthew G Pinto  5 , Simon Li  5 , Sarah B Kandil  1 , Marianne E Nellis  6 , Veronika Shabanova  1 , Cicero T Silva  7 , Joana A Tala  8 , Tara McPartland  9 , Philip C Spinella  10 ; for the CRETE Trial Investigators and the Pediatric Critical Care Blood Research Network (BloodNet) of the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI); CRETE Trial Investigators: Clinical Coordinating Center:; and; Data Coordinating Center:; and; Outcomes Adjudication Committee:; and; Data and Safety Monitoring Board:; and; Independent Safety Monitor:; and; Children’s Hospital Wisconsin:; and; Dell Children’s Medical Center:; and; Maria Fareri Children’s Hospital:; and; St. Louis Children’s Hospital:; and; University of Rochester Golisano Children’s Hospital:; and; Weill Cornell Medical Center:; and; and Yale-New Haven Children’s Hospital:; and; for the CRETE Trial Investigators and the Pediatric Critical Care Blood Research Network (BloodNet) of the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) and CRETE Trial Investigators: Clinical Coordinating Center: and and and Data Coordinating Center: and and and Outcomes Adjudication Committee: and and and Data and Safety Monitoring Board: and and and Independent Safety Monitor: and and and Children’s Hospital Wisconsin: and and and Dell Children’s Medical Center: and and and Maria Fareri Children’s Hospital: and and and St. Louis Children’s Hospital: and and and University of Rochester Golisano Children’s Hospital: and and and Weill Cornell Medical Center: and and and and Yale-New Haven Children’s Hospital: and and
Collaborators, Affiliations
Clinical Trial

Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial

E Vincent S Faustino et al. Crit Care Med. .

Abstract

Objectives: We explored the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against central venous catheter-associated deep venous thrombosis in critically ill children.

Design: Post hoc analysis of a Bayesian phase 2b randomized clinical trial.

Setting: Seven PICUs.

Patients: Children less than 18 years old with newly inserted central venous catheter.

Interventions: Enoxaparin started less than 24 hours after insertion of central venous catheter and adjusted to anti-Xa level of 0.2-0.5 international units/mL versus usual care.

Measurements and main results: Of 51 children randomized, 24 were infants less than 1 year old. Risk ratios of central venous catheter-associated deep venous thrombosis with prophylaxis with enoxaparin were 0.98 (95% credible interval, 0.37-2.44) in infants and 0.24 (95% credible interval, 0.04-0.82) in older children greater than or equal to 1 year old. Infants and older children achieved anti-Xa level greater than or equal to 0.2 international units/mL at comparable times. While central venous catheter was in situ, endogenous thrombin potential, a measure of thrombin generation, was 223.21 nM.min (95% CI, 8.78-437.64 nM.min) lower in infants. Factor VIII activity, a driver of thrombin generation, was also lower in infants by 45.1% (95% CI, 15.7-74.4%). Median minimum platelet count while central venous catheter was in situ was higher in infants by 39 × 103/mm3 (interquartile range, 17-61 × 103/mm3). Central venous catheter:vein ratio was not statistically different. Prophylaxis with enoxaparin was less efficacious against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and at higher platelet count.

Conclusions: The relatively lesser contribution of thrombin generation on central venous catheter-associated thrombus formation in critically ill infants potentially explains the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin.

Trial registration: ClinicalTrials.gov NCT03003390.

PubMed Disclaimer

Conflict of interest statement

Drs. Faustino and Spinella received funding to conduct the Catheter-Related Early Thromboprophylaxis with Enoxaparin Trial. Dr. Faustino’s institution received funding from National Institutes of Health (NIH) and the American Heart Association to conduct the trial (16RNT31180018). Drs. Faustino and Spinella received funding from the NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to conduct the trial (R21HD089131). Drs. Faustino, Hanson, Pinto, Shabanova, and McPartland received support for article research from the NIH. Drs. Faustino, Raffini, Hanson, Kandil, McPartland, and Spinella disclosed off-label product use of enoxaparin (investigational new drug approval from the U.S. Food and Drug Administration was received). Dr. Raffini received funding from Bayer, Genetech, Xa-Tek, and HemaBiologics. Dr. Hanson’s institution received funding from the NIH. Dr. Kandil received funding from Children’s Hospital Collaborative, Improving Pediatric Sepsis Outcomes. Dr. Shabanova’s institution received funding from Prevention of Central Venous Catheter-Associated Thrombosis in Critically Ill Children NICHD: R21HD089131; she received funding through the Clinical and Translational Science Award Grant Number UL1 RR024139 from the National Center for Research Resources and the National Center for Advancing Translational Science, components of the NIH, and NIH Roadmap for Medical Research. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Posterior distributions of the risk ratio of central venous catheter-associated deep venous thrombosis (CADVT) with prophylaxis with enoxaparin in critically ill infants and older children. The vertical line represents the posterior median of the probability distribution of the risk ratio. CrI – credible interval.
Figure 2.
Figure 2.
Kaplan-Meier curves of the probabilities of receiving enoxaparin (A) and achieving anti-Xa level ≥0.2 IU/mL (B) between critically ill infants and older children.
Figure 3.
Figure 3.
Endogenous thrombin potential (ETP; A), factor VIII activity (B) and D-dimer level (C) across different sampling times in critically ill infants and older children.
Figure 4.
Figure 4.
Effect of factor VIII activity (A) and platelet count (B and C) on the risk ratio of CVC-associated DVT (CADVT) with prophylaxis with enoxaparin. Higher risk ratios of CADVT with prophylaxis with enoxaparin, i.e., risk ratios that approached 1, indicated minimal reductions in the risk of CADVT with prophylaxis with enoxaparin and less efficacy. Conversely, lower risk ratios, i.e., risk ratios that approached 0, indicated significant reductions in the risk of CADVT with prophylaxis with enoxaparin and greater efficacy.
See this image and copyright information in PMC

References

    1. Raffini L, Huang YS, Witmer C, Feudtner C: Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124(4):1001–1008 - PubMed
    1. Mahajerin A, Branchford BR, Amankwah EK, Raffini L, et al.: Hospital-associated venous thromboembolism in pediatrics: A systematic review and meta-analysis of risk factors and risk assessment models. Haematologica 2015; 100(8):1045–1050 - PMC - PubMed
    1. Faustino EV, Raffini LJ: Prevention of hospital-acquired venous thromboembolism in children: A review of published guidelines. Front Pediatr 2017; 5:9. - PMC - PubMed
    1. Monagle P, Chan AK, Goldenberg NA, Ichord RN, et al.: Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl):e737S–801S - PMC - PubMed
    1. Monagle P, Cuello CA, Augustine C, Bonduel M, et al.: American Society of Hematology 2018 Guidelines for management of venous thromboembolism: Treatment of pediatric venous thromboembolism. Blood Adv 2018; 2(22):3292–3316 - PMC - PubMed

Publication types

Associated data